HAYA, RenBio Launch with Sights Set on Clinic


Two different companies, cardiac fibrosis RNA company HAYA Therapeutics and COVID-19 bispecific player RenBio, launched today with funding rounds designed to push them toward the clinic.

New York-based RenBio announced a $24 million series A round, led by Ruentex Group, to move its lead bispecific antibody into phase 1/2 trials by the end of the year. The asset was licensed from the laboratory of David Ho, a professor of microbiology and immunology at Colombia University and RenBio co-founder. Ho has previously pioneered research into bispecific antibodies for HIV therapies, and in a paper published last July in Nature , the group showed it had isolated SARS-CoV-2 virus-neutralizing monoclonal antibodies, including two that targeted the spike protein.